InspireMD announced a 122% year-over-year revenue increase to $3.4 million in Q1 2026, driven by strong demand for its CGuard Prime carotid stent system. The company received FDA approval to start the CGUARDIANS III clinical trial for its next-gen SwitchGuard neuro protection system in TCAR procedures and expects FDA approval for its original CGuard delivery system by Q3 2026. Despite a voluntary recall of the CGuard Prime 135 cm delivery system for technical improvements, InspireMD remains confident in its product enhancements and market growth potential, aiming to expand its addressable market with the upcoming CGuard Prime 80 cm approval in H2 2026.
Nuvei announced it will acquire Payoneer in an all-cash deal valued at $2.75 billion, offering Payoneer shareholders $7.40 per share. The merger aims to create a global commerce platform supporting businesses in over 190 countries, enhancing payment ...
Eli Lilly announced that its Phase 3 BRUIN CLL-322 trial showed adding Jaypirca (pirtobrutinib) to venetoclax and rituximab significantly improved progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or...
The osteoarthritis market is projected to grow at a moderate CAGR of 3% from 2026 to 2036, driven by an aging population and increasing disease prevalence. Emerging therapies like LEVI-04, ZILOSUL, TissueGene-C, and others are expected to enter the m...
A class action lawsuit has been filed against Nano-X Imaging Ltd. and some of its officers, accusing them of making false and misleading statements about the company's operations and prospects between March 31, 2025, and April 17, 2026. The lawsuit c...
Rhythm Pharmaceuticals reported encouraging six-month Phase 2 trial results for setmelanotide in patients with Prader-Willi syndrome, showing improvements in BMI, body composition, hyperphagia, and behavior. The study involved 18 patients aged 6 to 2...
